Marc Recht

Cooley advised Keros Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its $375 million capital return program, which represents the culmination of Keros’ strategic review process, including its share purchase agreements to repurchase all shares of its common stock beneficially owned by ADAR1 Capital Management and Pontifax Venture Capital and planned tender offer for up to $194 million in value of shares of its common stock.

Cooley advised Valneva, a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs, on a debt facility for up to $500 million in nondilutive financing with funds managed by Pharmakon Advisors.

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Cooley advised Eagle Pharmaceuticals, a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, on its cooperation agreement with Nantahala Capital Management, a holder of approximately 38% of Eagle’s outstanding shares.

Cooley advised Cerberus Ventures, a venture fund established in 2023 to invest in early-stage companies in sectors important to government and innovators, as lead investor in Syntis Bio’s $38 million financing. Partners Matthew Bartus, Marc Recht and Christophe Beauduin led the Cooley team advising Cerberus Ventures.